Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication June 17, 2014
- Accepted for publication August 12, 2014
- Published online November 3, 2014.
Article Versions
- previous version (October 6, 2014 - 05:24).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Haïfa Bahri1,
- Lenoir Laurence1–3,
- Julien Edeline2–4,
- Houda Leghzali1,
- Anne Devillers1,
- Jean-Luc Raoul5,
- Marc Cuggia6,
- Habiba Mesbah7,
- Bruno Clement2,
- Eveline Boucher2,4 and
- Etienne Garin1–3
- 1Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Rennes, France
- 2Inserm, UMR991, Liver Metabolisms and Cancer, Rennes, France
- 3University of Rennes 1, Rennes, France
- 4Department of Medical Oncology, Cancer Institute Eugène Marquis, Rennes, France
- 5Department of Medical Oncology, Comprehensive Cancer Center, Institute Paoli Calmette, Marseille, France
- 6Department of Medical Computing, CHU Pontchaillou, Rennes, France; and
- 7Department of Medical Informations, Cancer Institute Eugène Marquis, Rennes, France
- For correspondence or reprints contact: Etienne Garin, Centre Eugène Marquis, Rennes CS 44229, F-35042 Rennes, France. E-mail: e.garin{at}rennes.unicancer.fr
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- [18F]FDG and [68Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms
- Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors
- [18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
- High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe detude des Tumeurs Endocrines and ENDOCAN-RENATEN Network
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study
- Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors
- Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms
- The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase {gamma}, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia
- Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
- The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review
- Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
- Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions
- Prognostic Value of FDG-PET/CT Total Lesion Glycolysis for Patients with Resectable Distal Bile Duct Adenocarcinoma
- Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas
- Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)
- Reply: Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)